新型降糖药物替西帕肽的临床研究进展  

Clinical Research Progress of Tirzepatide:a New Hypoglycemic Agent

作　　者：张丽娜[1] 王岩[1] 张抗怀[1] 李友佳[1] ZHANG Lina;WANG Yan;ZHANG Kanghuai;LI Youjia(Department of Pharmacy,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China)

机构地区：[1]西安交通大学第二附属医院药学部,陕西省西安市710004

出　　处：《中国全科医学》2023年第15期1902-1908,共7页Chinese General Practice

基　　金：中国药学会全国医药信息网科普研究重点项目(CMEI2022KPYJ00228)。

摘　　要：目前全球有多种治疗糖尿病的药物,但仍有很多糖尿病患者未能达到推荐的目标血糖水平,研发和应用新型降糖药迫在眉睫。2022年5月,美国食品药品监督管理局(FDA)批准葡萄糖依赖性促胰岛素多肽(GIP)和胰高糖素样肽-1(GLP-1)双重受体激动剂替西帕肽上市,辅助饮食和运动,每周注射1次以改善成人2型糖尿病患者的血糖控制。多项临床研究已验证其用于2型糖尿病的有效性和安全性,同时该药在肥胖症、心血管风险相关疾病、非酒精性脂肪性肝炎等疾病治疗方面也具有潜在的应用价值。本文通过对替西帕肽的作用机制、有效性和安全性进行综述,为其在我国上市后的临床应用提供参考。Despite the availability of various drugs for the treatment of diabetes worldwide,many patients still fail to achieve the recommended target blood sugar levels. Therefore,it is urgent to develop and apply new hypoglycemic drugs. In May 2022,FDA approved tirzepatide,a dual receptor agonist for GIP and GLP-1,administrated once a week to improve blood glucose control in adults with type 2 diabetes by assisting diet and exercise. Numerous clinical studies have proven its effectiveness and safety in type 2 diabetes,and its potential applications in obesity,cardiovascular diseases,non-alcoholic steatohepatitis and so on. In this paper,the mechanism of action,efficacy and safety of tirzepatide were reviewed to provide a reference for its clinical application after marketed in China.

关 键 词：糖尿病 2型 降血糖药 替西帕肽 葡萄糖依赖性促胰岛素多肽/胰高糖素样肽-1受体激动剂 肥胖症 有效性 安全性 综述 

分 类 号：R587.1[医药卫生—内分泌]